fingolimod hydrochloride has been researched along with Anti-MuSK Myasthenia Gravis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Du, T; Duan, RS; Ge, MR; Li, H; Li, XL; Lian, Y; Liu, Y; Liu, YD; Yang, B; Yang, CL; Zhang, P | 1 |
1 other study(ies) available for fingolimod hydrochloride and Anti-MuSK Myasthenia Gravis
| Article | Year |
|---|---|
Prophylactic administration of fingolimod (FTY720) ameliorated experimental autoimmune myasthenia gravis by reducing the number of dendritic cells, follicular T helper cells and antibody-secreting cells.
Topics: Animals; Antibody-Producing Cells; Autoantigens; Dendritic Cells; Disease Models, Animal; Female; Fingolimod Hydrochloride; Humans; Immunity, Humoral; Immunosuppressive Agents; Myasthenia Gravis; Myasthenia Gravis, Autoimmune, Experimental; Peptides; Rats; Rats, Inbred Lew; Receptors, Cholinergic; T-Lymphocytes, Helper-Inducer | 2021 |